Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine safety, tolerability, dose limiting toxicities
(DLT) and maximum tolerated dose (MTD) of ZEN003365 in patients with relapsed/refractory
lymphoproliferative malignancies (LPM) or relapsed/refractory acute myeloid leukemia (AML).